Revolutionising Medicine with Advanced

Oligonucleotide and Peptide Therapeutics.

Pioneering TIDES expertise in oligonucleotide and peptide synthesis, specializing in Therapeutic Oligonucleotides and Peptides for Active Pharmaceutical Ingredients (APIs). Our cutting-edge technologies deliver high-purity, scalable solutions for therapeutic applications.

Custom Oligonucleotides

Tailored DNA, RNA, and modified oligos for advanced therapeutics

Oligonucleotide Therapeutics

High-purity ASOs, siRNAs, and aptamers for targeted disease treatment

Peptide Therapeutics

Generic peptide APIs and finished drugs for metabolic and oncological therapies

1 of 3
Synthesis illustration

Our API Portfolio

Discover our comprehensive range of high-quality APIs, manufactured with precision and certified to the highest international standards.

Featured
Drug Substance and Drug Product for SMA Treatment
Neurology
Specialized antisense oligonucleotide API for Spinal Muscular Atrophy (SMA) treatment, manufactured using Antisense Technology. Provides both API and finished product for seamless drug development and clinical applications, ensuring quality, scalability, and regulatory compliance.
Scale Range:1mg - 10gm
Purity:≥99.8%
Applications:
Spinal Muscular AtrophyIntrathecal
Certifications:
FDAEMAICH
Featured
DMD Treatment API Complex
Neurology
Innovative phosphorodiamidate morpholino oligomer (PMO) API for Duchenne Muscular Dystrophy (DMD) treatment, manufactured via oligonucleotide synthesis. Offers API and finished product for drug development and patient care, with a focus on quality and scalability.
Scale Range:1mg - 10mg
Purity:≥99.5%
Applications:
Duchenne Muscular DystrophyNeuromuscular
Certifications:
FDAEMAICH
ASCVD Treatment API Complex
Cardiovascular
Advanced small interfering RNA (siRNA) oligonucleotide API for Atherosclerotic Cardiovascular Disease (ASCVD) treatment, manufactured using siRNA technology. Provides API and finished product for clinical applications, ensuring regulatory compliance and scalability.
Scale Range:1mg - 100gm
Purity:≥99.5%
Applications:
Atherosclerotic Cardiovascular DiseaseCardiovascular
Certifications:
FDAEMAICH
Featured
Type 2 Diabetes Mellitus and Obesity Treatment API Complex
Metabolic
GLP-1 agonist peptide API for Type 2 Diabetes Mellitus (T2DM) and obesity treatment, manufactured via Peptide SPPS method. Offers API and finished product for drug development, with a commitment to quality, scalability, and regulatory compliance.
Scale Range:1gm - 300gm
Purity:≥99.5%
Applications:
Type 2 DiabetesObesity+1 more
Certifications:
FDAEMAICH
Short Bowel Syndrome Treatment API Complex
Gastroenterology
GLP-2 agonist peptide API for Short Bowel Syndrome (SBS) treatment, manufactured via Peptide SPPS method. Provides API and finished product for clinical applications, ensuring quality, scalability, and regulatory compliance.
Scale Range:1gm - 300gm
Purity:≥99.5%
Applications:
Short Bowel Syndrome
Certifications:
FDAEMAICH
Acromegaly and Thyrotrophinomas Treatment API Complex
Endocrinology
Somatostatin analog peptide API for Acromegaly and Thyrotrophinomas treatment, manufactured via Peptide SPPS method. Offers API and finished product for drug development, with a focus on quality and regulatory compliance.
Scale Range:1gm - 300gm
Purity:≥99.5%
Applications:
AcromegalyThyrotrophinomas+1 more
Certifications:
FDAEMAICH
1 of 6

Excellence in every batch delivered

Our stringent quality assurance ensures API reliability through advanced analytical testing, HPLC, HRMS, NMR, and CE-MS. With GMP-compliant facilities and USP standards, we deliver high-purity, compliant APIs consistently.

HPLC TestingMass SpectrometryGMP StandardsUSP GuidelinesBioactivity AssaysPurity AnalysisEndotoxin TestingImpurity ProfilingNMR Analysis

Our Product Portfolio

Discover breakthrough pharmaceutical innovations shaping the future of healthcare

Nuclisiran

Nuclisiran

Advanced RNA interference therapeutic targeting PCSK9 for cholesterol management. Breakthrough technology showing promising results in cardiovascular disease prevention.

RNA InterferenceCardiovascular
Inclisiran

Inclisiran

Revolutionary siRNA therapy for lowering LDL cholesterol with twice-yearly dosing. FDA-approved treatment changing the landscape of lipid management.

siRNALDL Cholesterol
Etplisiran

Etplisiran

Next-generation RNAi therapeutic for hereditary transthyretin-mediated amyloidosis. Innovative approach to treating rare genetic diseases.

RNAiAmyloidosis
Semaglutide

Semaglutide

GLP-1 receptor agonist revolutionizing diabetes and obesity treatment. Weekly injection showing remarkable efficacy in weight management.

GLP-1Diabetes
Liraglutide

Liraglutide

Proven GLP-1 analog for diabetes management and cardiovascular protection. Daily therapy with established safety profile and clinical benefits.

GLP-1 AnalogCardiovascular
Synthesis illustration

Synthesis Capabilities

Advanced synthesis of precision oligonucleotides, peptides, and custom molecules available at Dansk, enabling innovative pharmaceutical solutions.

Oligonucleotide Synthesis Capabilities

Advanced synthesis of precision oligonucleotides for therapeutic APIs, utilizing state-of-the-art solid-phase synthesis technologies to produce antisense oligonucleotides (ASOs), siRNAs, and PMOs with high precision and scalability for applications in neuromuscular disorders, cardiovascular diseases, and metabolic conditions.

Key Capabilities:

  • Antisense oligonucleotides (ASOs) for targeted gene modulation
  • siRNAs for RNA interference therapies
  • PMOs for splice-modulating applications
  • Custom modifications: Phosphorothioate backbone, GalNAc conjugation, Cholesterol attachment
  • Additional enhancements: 2'-O-methyl, 2'-fluoro, and MOE modifications
  • Solid-phase synthesis with GMP compliance and high scalability
Research-gradeGMP-compliantCommercial-scale
Technical Specifications
Purity≥95%
Scale Rangemg to kg
Coupling Efficiency≥98%

ÄKTA Oligosynt™

Research-scale optimization

MerMade 192X

192 parallel synthesis channels

Flow Reactors

Continuous synthesis systems

1 of 3
Purification illustration

Purification Technology

Pharma-Grade Purity at Scale – From R&D to commercial production. Our purification platforms deliver exceptional purity and consistency for peptides and oligonucleotides.

Peptide Purification

DAC columns for R&D to commercial production

Capabilities:

  • DAC columns (50-150 mm) for R&D (10-500g)
  • 300 mm DAC for large-scale production
  • HPFC and RP-HPLC purification on C18 columns

Specifications:

Purity Achievement>98%
Scale Range10g-5kg
Resolution>99%
Oligonucleotide Purification

Insintech automated purification systems

Capabilities:

  • Insintech system (25-100 mm) automated
  • Supports >95% oligo purity
  • Gradient-optimized solvent delivery

Specifications:

Oligo Purity>95%
Retention Time±0.1 min
Modified BasesSupported
TFF Systems

Tangential Flow Filtration for desalting & buffer exchange

Capabilities:

  • Desalting & buffer exchange
  • Up to 100L per batch
  • Supports peptide and oligo pipelines

Specifications:

Batch Volume100L
Moisture Control>95%
Solvent RecoveryEthanol/ACN
1 of 3
Chromatographic Excellence
HPLC Techniques
Reverse-phase and ion-exchange HPLC
Purity Levels
>99% purity for API production
Compliance
GMP, FDA, EMA standards
Recovery & Processing
Loading Capacity
mg to kg-scale columns
Yield Efficiency
High yields for oligonucleotides/peptides
Traceability
Full audit and batch traceability
Scale Up illustration

Facilities & Scale-Up

Precision in Molecular Engineering across oligonucleotides, peptides, and dual conjugates. Our advanced synthesis platforms enable the creation of highly customized biomolecules with stringent quality control.

20,000 sq ft
GMP Facility
300-400 L
Max Reactor
500L
Lyophilizer
ISO 7 & 8
Cleanroom
Key Assets illustration

Key Assets

Explore our specialized equipment and infrastructure supporting advanced synthesis, purification, and analytics for complex biomolecules.

Synthesis

Mermade 192X

High-throughput

Up to 192 oligonucleotides

ÄKTA oligosyntTM

Operational

Small-scale

300L Reactor

Operational

300L

Pilot Scale Reactors

Available

10-100L

Purification

200L DAC Column

Operational

200L

Chromatography Systems

Automated

25-50mm columns

TFF Systems

Multi-unit

Up to 100L

Processing

Lyophilizer

Class 100,000

5L, 10L

Analytics

HPLC-MS

In-house QC

UHPLC capable

ICP-MS

QA Suite

Trace metals

Automation

Automated Handling Systems

High-throughput

Compound robots

1 of 5
Scale Capabilities
µg–mgBench-top
R&D
g–kgPilot plant
Preclinical, Trials
kg+GMP line
Commercial
Facility Layout

Interactive overview of our GMP-compliant production campus

R&D Labs
Synthesis & Development
Pilot Plant
Scale-up Operations
GMP Suite
Commercial Production
QC/QA Labs
Quality Control
Therapeutic illustration

Therapeutic Applications

Molecules That Make a Difference - Connecting product platforms to patient outcomes, bringing innovative therapies from laboratory to clinic.

Metabolic & Endocrine

GLP-1 Agonists

Phase II
Indications:
Type 2 diabetesObesityMASLD
Molecule:

Liraglutide analogs

Mechanism:

Enhance lipid metabolism and insulin secretion

Delivery: SC injection
Oncology

CPP-Conjugated Peptides

Preclinical
Indications:
Solid tumorsHematological cancers
Molecule:

Cell-penetrating peptides

Mechanism:

Targeted tumor delivery

Delivery: IV infusion
Neuromuscular Disorders

DMD Therapeutics

IND-enabling
Indications:
Duchenne MDSpinal disorders
Molecule:

CPP conjugates

Mechanism:

Muscle fiber regeneration

Delivery: Intramuscular
Genetic Disorders

SMA Treatment

Phase I
Indications:
Spinal Muscular Atrophy
Molecule:

ASOs (SMN2 modulation)

Mechanism:

PPMO formulations crossing BBB

Delivery: Intrathecal
Liver & Metabolic

GalNAc Conjugates

Phase II
Indications:
Liver diseasesMetabolic disorders
Molecule:

GalNAc-siRNA

Mechanism:

Targeting ApoB, PCSK9

Delivery: SC injection
1 of 5
Delivery illustration

Delivery Technologies

Advanced delivery platforms for precise, effective, and safe therapeutic targeting across tissues and disease areas.

GalNAc Conjugates

Liver-targeted delivery

Validated in vivo

CPP Systems

Cell-penetrating peptides

CNS targeted

Nanoparticle and inorganic systems

gold nanoparticles & silica nanoparticels

Muscle targeted

LNP Distribution

LNP liquid based delivery

Validated
1 of 4
Sustainability illustration

Sustainability

Green Science for Global Health - Committed to sustainable biopharma manufacturing

>90%
Solvent Recovery Rate

Advanced recovery systems

-60%
CO₂ Emissions Reduction

Via continuous flow

-50%
Water Usage Reduction

In-process recirculation

-60%
Energy Efficiency

Flow chemistry advantage

1 of 4
Green Initiatives illustration

Green Initiatives

Driving impactful change through solvent reduction, energy efficiency, waste management, and eco-friendly materials.

Solvent ReductionImplemented

Continuous synthesis saves up to 70% solvents

70% reduction
Energy EfficiencyActive

Flow chemistry reduces energy input by 60%

60% less energy
Waste ManagementOptimized

Real-time analytics to minimize off-spec material

85% waste reduction
Eco-Friendly MaterialsCertified

Phosphate-free reagents, reusable resins

100% animal-free
1 of 4
Sustainable Process Lifecycle

Circular "Green Loop" design showing synthesis-to-recovery lifecycle

Raw Materials

Eco-friendly sourcing

Synthesis

Continuous flow process

Purification

Solvent recovery

Final Product

Minimal waste output

Environmental Impact
Carbon Footprint Reduction-45%
Renewable Energy Usage75%
Waste Diversion Rate90%
Certifications & Standards
ISO 14001
Environmental Management
Green Chemistry Principles
12 Principles Compliance
Carbon Neutral Facility
2024 Target Achievement
100% Animal-Free
Production Inputs

Need a Custom API Solution?

Our expert team can develop and manufacture custom APIs tailored to your specific requirements, from micrograms to tons with complete regulatory compliance and quality assurance.